205 related articles for article (PubMed ID: 34610184)
1. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
2. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
4. Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma.
Kerr C; Adhikary G; Grun D; George N; Eckert RL
Mol Carcinog; 2018 Jan; 57(1):3-11. PubMed ID: 28796401
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.
Chen X; Adhikary G; Shrestha S; Xu W; Keillor JW; Naselsky W; Eckert RL
Mol Cancer Res; 2021 Dec; 19(12):2026-2035. PubMed ID: 34593609
[TBL] [Abstract][Full Text] [Related]
6. Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.
Saha K; Fisher ML; Adhikary G; Grun D; Eckert RL
Carcinogenesis; 2017 Aug; 38(8):827-836. PubMed ID: 28854561
[TBL] [Abstract][Full Text] [Related]
7. The transglutaminase 2 cancer cell survival factor maintains mTOR activity to drive an aggressive cancer phenotype.
Chen X; Adhikary G; Newland JJ; Xu W; Ma E; Naselsky W; Eckert RL
Mol Carcinog; 2023 Jan; 62(1):90-100. PubMed ID: 35848131
[TBL] [Abstract][Full Text] [Related]
8. Competitive Binding of Magnesium to Calcium Binding Sites Reciprocally Regulates Transamidase and GTP Hydrolysis Activity of Transglutaminase 2.
Jeong EM; Lee KB; Kim GE; Kim CM; Lee JH; Kim HJ; Shin JW; Kwon MA; Park HH; Kim IG
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31991788
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Ezeka G; Adhikary G; Kandasamy S; Friedberg JS; Eckert RL
Mol Carcinog; 2021 Jul; 60(7):429-439. PubMed ID: 33872411
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 Binds to the CD44v6 Cytoplasmic Domain to Stimulate CD44v6/ERK1/2 Signaling and Maintain an Aggressive Cancer Phenotype.
Chen X; Adhikary G; Newland JJ; Xu W; Keillor JW; Weber DJ; Eckert RL
Mol Cancer Res; 2023 Sep; 21(9):922-932. PubMed ID: 37227250
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition.
Prat-Duran J; Pinilla E; Nørregaard R; Simonsen U; Buus NH
Pharmacol Ther; 2021 Jun; 222():107787. PubMed ID: 33307141
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane regulates the proliferation of leukemia stem-like cells via Sonic Hedgehog signaling pathway.
Wang F; Huang X; Sun Y; Li Z; Sun R; Zhao T; Wang M; Yan C; Liu P
Eur J Pharmacol; 2022 Mar; 919():174824. PubMed ID: 35157913
[TBL] [Abstract][Full Text] [Related]
13. Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays.
Ganai SA; Srinivasan P; Rajamanikandan S; Shah BA; Mohan S; Gani M; Padder BA; Qadri RA; Bhat MA; Baba ZA; Yatoo MA
Chem Biol Drug Des; 2021 Sep; 98(3):363-376. PubMed ID: 33966346
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor PP242 increases antitumor activity of sulforaphane by blocking Akt/mTOR pathway in esophageal squamous cell carcinoma.
Lu Z; Zhang Y; Xu Y; Wei H; Zhao W; Wang P; Li Y; Hou G
Mol Biol Rep; 2022 Jan; 49(1):451-461. PubMed ID: 34731371
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
[TBL] [Abstract][Full Text] [Related]
16. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.
Ulukan B; Bihorac A; Sipahioglu T; Kiraly R; Fesus L; Telci D
ACS Omega; 2020 Nov; 5(43):28273-28284. PubMed ID: 33163811
[TBL] [Abstract][Full Text] [Related]
17. Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.
Gates EWJ; Calvert ND; Cundy NJ; Brugnoli F; Navals P; Kirby A; Bianchi N; Adhikary G; Shuhendler AJ; Eckert RL; Keillor JW
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628729
[TBL] [Abstract][Full Text] [Related]
18. Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition.
Fisher ML; Adhikary G; Xu W; Kerr C; Keillor JW; Eckert RL
Oncotarget; 2015 Aug; 6(24):20525-39. PubMed ID: 25971211
[TBL] [Abstract][Full Text] [Related]
19. The Anti-Tumoral Potential of Phosphonate Analog of Sulforaphane in Zebrafish Xenograft Model.
Rudzinska-Radecka M; Janczewski Ł; Gajda A; Godlewska M; Chmielewska-Krzesinska M; Wasowicz K; Podlasz P
Cells; 2021 Nov; 10(11):. PubMed ID: 34831440
[TBL] [Abstract][Full Text] [Related]
20. The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation.
He C; Buongiorno LP; Wang W; Tang JCY; Miceli N; Taviano MF; Shan Y; Bao Y
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
